Meeting
2015 ASCO Annual Meeting
Crizotinib in advanced non-small-cell lung cancer with de novo c-Met overexpression.
Authors
An Na Li
Guangdong Lung Cancer Institute, Guangzhou, China
An Na Li , Jin-Ji Yang , Xu-Chao Zhang , Yi-Long Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8090)
DOI
10.1200/jco.2015.33.15_suppl.8090
Abstract #
8090
Poster Bd #
414
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Targeting c-Met overexpression for overcoming acquired resistance to EGFR TKIs in NSCLC.
First Author: Lanying Gou Jr.
Poster
2018 ASCO Annual Meeting
An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.
First Author: Laura Mezquita
Poster
2022 ASCO Annual Meeting
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
First Author: Conor Ernst Steuer
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang